The present invention provides Fc-fused protein constructs, which as monovalent dimers have a higher serum half-life compared to a native/natural molecule, and are, therefore, advantageous for achieving higher titers of the proteins during production, higher stability during storage, and improved efficacy when used as a therapeutic. Also provided are Fc-fused protein constructs having mutations in the Fc region that reduce effector functions, which have increased activity to inhibit tumor growth and are, therefore, advantageous when used as a cancer therapy.本發明提供Fc融合蛋白構築體，其作為單價二聚體相較於原生/天然分子具有較高血清半衰期，且因此有利於達成蛋白質在生產期間之較高效價、在儲存期間之較高穩定性及用作治療劑時之改良功效。亦提供在Fc區具有降低效應功能之突變的Fc融合蛋白構築體，其對抑制腫瘤生長之活性增加且因此有利於用作癌症療法。
